DNMT3A mutations in myeloproliferative neoplasmsSTEGELMANN, F; BULLINGER, L; SCHLENK, R. F et al.Leukemia. 2011, Vol 25, Num 7, pp 1217-1219, issn 0887-6924, 3 p.Article

Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance developmentBURCHERT, A; WANG, Y; CAI, D et al.Leukemia. 2005, Vol 19, Num 10, pp 1774-1782, issn 0887-6924, 9 p.Article

Deregulated apoptosis signaling in core-binding factor leukemia differentiates clinically relevant, molecular marker-independent subgroupsLÜCK, S. C; RUSS, A. C; BOTZENHARDT, U et al.Leukemia. 2011, Vol 25, Num 11, pp 1728-1738, issn 0887-6924, 11 p.Article

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon αMERX, K; MÜLLER, M. C; HEHLMANN, R et al.Leukemia. 2002, Vol 16, Num 9, pp 1579-1583, issn 0887-6924Article

Dynamics of BCR-ABL mRNA expression in first-line therapy of chronic myelogenous leukemia patients with imatinib or interferon α/ara-CMÜLLER, M. C; GATTERMANN, N; KRAUSE, S. W et al.Leukemia. 2003, Vol 17, Num 12, pp 2392-2400, issn 0887-6924, 9 p.Article

Frequent polymorphism in BCR exon b2 identified in BCR-ABL positive and negative individuals using fluorescent hybridization probesSAUSSELE, S; WEISSEER, A; MÜLLER, M. C et al.Leukemia. 2000, Vol 14, Num 11, pp 2006-2010, issn 0887-6924Article

Lack of clinical efficacy of imatinib in metastatic melanomaUGUREL, S; HILDENBRAND, R; SCHADENDORF, D et al.British journal of cancer. 2005, Vol 92, Num 8, pp 1398-1405, issn 0007-0920, 8 p.Article

Molecular monitoring of response to imatinib (Glivec®) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission : Spotlight on imatinib as a model for signal transduction inhibitorsPASCHKA, P; MÜLLER, M. C; GSCHAIDMEIER, H et al.Leukemia. 2003, Vol 17, Num 9, pp 1687-1694, issn 0887-6924, 8 p.Article